July 20, 2018
- FDA approves Tibsovo (ivosidenib), the first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
- FDA Drug Shortages
- Aminocaproic Acid Injection, USP (Updated - Currently in Shortage)
- Atropine Sulfate Injection (Updated - Currently in Shortage)
- Bupivacaine Hydrochloride and Epinephrine Injection, USP (Updated - Currently in Shortage)
- Bupivacaine Hydrochloride Injection, USP (Updated - Currently in Shortage)
- Calcium Chloride Injection, USP (Updated - Currently in Shortage)
- Dextrose 50% Injection (Updated - Currently in Shortage)
- Dobutamine Hydrochloride Injection (Updated - Currently in Shortage)
- Fentanyl Citrate (Sublimaze) Injection (Updated - Currently in Shortage)
- Heparin Sodium and Sodium Chloride 0.9% Injection (Updated - Currently in Shortage)
- Hydromorphone Hydrochloride Injection, USP (Updated - Currently in Shortage)
- Ketamine Injection (Updated - Currently in Shortage)
- Ketorolac Tromethamine Injection (Updated - Currently in Shortage)
- Labetalol Hydrochloride Injection (Updated - Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection (Updated - Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection with Epinephrine (Updated - Currently in Shortage)
- Lorazepam Injection, USP (Updated - Currently in Shortage)
- Magnesium Sulfate Injection (Updated - Currently in Shortage)
- Morphine Sulfate Injection, USP (Updated - Currently in Shortage)
- Ondansetron Hydrochloride Injection (Updated - Currently in Shortage)
- Piperacillin and Tazobactam (Zosyn) Injection (Updated - Currently in Shortage)
- Potassium Chloride Injection (Updated - Currently in Shortage)
- Ropivacaine Hydrochloride Injection (Updated - Currently in Shortage)
- Sodium Acetate Injection, USP (Updated - Currently in Shortage)
- Sodium Chloride 23.4% Injection (Updated - Currently in Shortage)
- Sodium Chloride Injection USP, 0.9% Vials (Updated - Currently in Shortage)
- Sterile Water (Updated - Currently in Shortage)
- Product-Specific Guidances for Generic Drug Development (updated)
No hay comentarios:
Publicar un comentario